Abstract
We performed the dye exclusion assay (DEA) and the MTT dye reduction assay to determine the drug sensitivity of acute leukemia using short-term microplate cultures. The in vitro results were compared with the clinical response of 31 patients with acute leukemia treated by combination chemotherapy. The true-positive rates of the DEA and MTT assays were 86.7 and 91.3%, respectively; the true-negative rates were 33.3 and 77.8%, respectively; and the predictive accuracy was 62.5 and 87.5%, respectively. The DEA and MTT assays gave comparable results in drug sensitivity testing of leukemic blast cells. Our data suggest that MTT assay is the more suitable for assessing chemosensitivity in acute leukemia.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / toxicity*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow / pathology*
-
Coloring Agents
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Drug Screening Assays, Antitumor / methods*
-
Female
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Male
-
Middle Aged
-
Mitoxantrone / therapeutic use*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
Prednisolone / therapeutic use
-
Prognosis
-
Tetrazolium Salts
-
Thiazoles
Substances
-
Antineoplastic Agents
-
Coloring Agents
-
Tetrazolium Salts
-
Thiazoles
-
Cytarabine
-
Prednisolone
-
Mitoxantrone
-
thiazolyl blue
-
Daunorubicin